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Background: The World Health Organization estimates that 536 million people aged 15–49 are infected with
Herpes simplex virus type 2 (HSV-2), the causative agent of genital herpes. The aim of this study was to investigate
the role of behavioral and demographic factors that contribute to the high HSV-2 sero-prevalence among women
participating in a HIV prevention trial. The Methods for Improving Reproductive Health in Africa (MIRA) study assessed
the effectiveness the latex diaphragm and lubricant gel on HIV prevention among women in South Africa and
Zimbabwe. At screening an interviewer administered questionnaire on demographics and sexual behaviour was
obtained. HSV-2 serum antibodies were detected using HerpeSelect™ ELISA IgG. Statistical analysis was performed
using STATA release 12.0. This study was registered with ClinicalTrials.gov,number NCT00121459 on the 28th
February 2007.
Findings: Of the 3 472 women screened at the Durban research sites 2 218 (73%) had a prevalent HSV-2 infection
and 1431 (41%) of the women were also co-infected with HIV. In the multivariate analyses, older women (adjusted
odds ratio) [aOR]: 3.49, 95% CI: (2.71,4.49) for >35 years and aOR: 1.82, 95% CI: 1.49, 2.22 for 25–34 years compared
with <25 years, p < 0.001 for both comparisons were more likely to be HSV-2 sero-positive. Low level of education
(OR: 1.26 95% CI: 1.03, 1.53), having >1 life-time sexual partners (OR: 2.48, 95% CI: 1.92, 3.20), parity >1 (OR: 1.95 95% CI:
1.92, 3.20) and being HIV positive (OR: 6.31, 95% CI: 5.06, 7.88) were significantly associated with HSV-2 infection.
Conclusion: The high sero-prevalence of HSV-2 in the studied population is of great public health importance
since this high risk population could act as a reservoir for future infections particularly HIV transmission.
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While bacterial sexually transmitted infections (STIs) such
as Chlamydia and Gonorrhoea are curable, viral STIs such
as herpes simplex virus, human papillomavirus, hepatitis B
and Human immunodeficiency virus (HIV) are deemed to
be persistent and incurable [1,2]. The World Health
Organization estimates that 536 million people aged
15–49 are infected with Herpes simplex virus type 2
(HSV-2), the causative agent of genital herpes [3]. Annu-
ally approximately 23.6 million people in this age group
become newly infected with HSV-2. The prevalence rates
of HSV-2 infection are reported to be higher in women* Correspondence: Nathlee.abbai@mrc.ac.za
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unless otherwise stated.when compared to men; with the lowest prevalence rates
being 13% among West European men and the highest
prevalence rates being 70% among sub-Saharan African
women [3]. There are several reports suggesting that
HSV-2 is a biological co-factor for HIV acquisition [4-7].
A meta-analysis performed by Freeman [8] showed that
the relative risk of HIV acquisition associated with HSV-2
was 3.1 (95% confidence interval (CI): 1.7, 5.6). It is sug-
gested that HSV-2 infection may contribute to >50% new
HIV infections among women in Sub-Saharan Africa [9].
In South Africa, the prevalence of HSV-2 infection is re-
ported to be 53% [10].
The aim of this analysis was to investigate the role of
behavioural and demographic factors that contribute to
the high HSV-2 sero-prevalence among women participat-
ing in a HIV prevention trial. The Methods for ImprovingThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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conducted between 2003–2005 assessed the effectiveness
the latex diaphragm and lubricant gel on HIV prevention
among women in South Africa and Zimbabwe [11]. In
Durban, the study was conducted in rural Umkomaas and
Bothas Hill, southern and western Durban. The study
protocol and informed consents were approved by the
Biomedical Research Ethics Committee of the University
of KwaZulu-Natal. Participants provided written informed
consent prior to study procedures being conducted.
At screening, verbal consent to assess initial eligibility,
followed by written informed consent for screening pro-
cedures, including diagnostic testing and answering an
interviewer administered questionnaire on demographics
and sexual behaviour was obtained. The full details of this
study are described elsewhere [11]. The presence of HSV-
2 antibodies was detected using HerpeSelect™ ELISA IgG
(Focus Technologies, Cypress, CA, USA) according to the
manufacturer’s recommendations with a cut-off value of
1.1. Two HIV rapid tests were done on whole blood
samples from venipuncture by use of Determine HIV-1/
2 (Abbott Laboratories, Japan) and Oraquick (OraSure
Technologies, USA). Urine specimens were collected for
polymerase chain reaction (PCR) testing for Neisseria
gonorrhea (NG), Chlamydia trachomatis (CT) and Tricho-
monas vaginalis (TV) (Roche Pharmaceuticals, USA).
Univariate and multivariate analyses were performed using
logistic regression for both. Multivariate models consid-
ered all variables statistically significant (P < 0.10) in the
initial analyses and used a forward stepwise method. Stat-
istical analysis was performed using STATA release 12.0
(College Station, Texas, TX, USA).
Of the 3 472 women screened at the Durban research
sites 2 218 (73%) had a prevalent HSV-2 infection
(Table 1). According to the univariate analyses, socio-
demographic associations such as being older (25 years
and older) (Odds Ratio (OR) 2.37, 95% Confidence
Interval (CI): 2.00,2.81), belonging to a particular eth-
nic group based on language spoken i.e. isiZulu (OR:
5.47, 95% CI: 4.01, 7.43) having less than high school
education (OR: 1.68, 95% CI: 1.43, 1.98), being single/
non-cohabiting (OR: 1.54, 95% CI: 1.25, 1.89), and be-
longing to a particular religion (Christianity) (OR: 1.72,
95% CI: 1.36, 2.18) were significantly associated with
HSV-2 infection. The behavioural and biological factors
that were significantly associated with HSV-2 infection
were: age of sexual debut (<16 years old) (OR: 1.40,
95% CI: 1.19, 1.63), >4 lifetime sexual partner (OR: 5.43
95% CI: 4.33, 6.82) parity >1 (OR: 2.31, 95% CI: 1.90,2.80),
lack of contraceptive use (OR: 1.40, 95% CI: 1.26, 1.68),
co-infection with Neisseria gonorrhoeae (OR: 2.28, 95%
CI: 1.29, 4.05) presenting with a genital ulcer (OR: 3.16,
95% CI: 1.73, 5.74) and being HIV positive (OR: 7.38, 95%
CI: 6.01, 9.10).In the multivariate analyses, older women (25 years
and older) were more likely to be HSV-2 sero-positive
(OR: 1.82, 95% CI: 1.49, 2.22). Women with a lower level
of education were also considered to be more likely to be
HSV-2 positive (OR: 1.26 95% CI: 1.03, 1.53). Additionally,
having >1 life-time sexual partners (OR: 2.48, 95% 1.92,
3.20) parity >1 (OR: 1.95 95% CI: 1.92, 3.20) and being
HIV positive (OR: 6.31, 95% CI 5.06, 7.88) were all signifi-
cantly associated with HSV-2 infection.
In this study, the prevalence of HSV-2 was estimated
at 73% with 41% of the women also co-infected with
HIV. Behavioural characteristics such as: a high number
of life-time sexual partners [12-15], older age [9,10,16,17],
parity >1 [15,17] and a low level of education [17] were
contributory factors. Biologically, being HIV positive
[9,15,16,18], was associated with the high HSV-2 sero-
prevalence seen in the study population. The data re-
ported in this study is consistent with previous studies
[9,10,16,17].
Consistent with other studies, older age is associated
with HSV-2 infection [9,10,16,17]. The prevalence of
HSV-2 infection in women with > 4 life-time sexual part-
ners was 2-fold higher when compared with women with
just one sexual partner. This finding is strongly supported
by previous studies conducted [12-15]. Parity was also
strongly associated with HSV-2 infection. Women with a
previous pregnancy had a 2-fold higher prevalence for
HSV-2 infection when compared to women that were nul-
liparous. Currently there is limited published literature
that explains the association between parity and HSV-2
infections. Older age and parity are probably surrogate
measures of cumulative sexual exposure. However, post-
partum susceptibility to HSV-2 will be best explained in a
prospective analysis. Our findings show that HSV-2 infec-
tions was higher in women with a lower level of education
(less than high-school education) as compared to women
with high-school education. This is consistent with the
findings of Uribe-Salas et al. [17].
In this study we found that women that were already
HIV positive had 6-fold greater odds of being co-infected
with HSV-2 than women that were HIV sero-negative.
HIV has been shown to enhance the genital shedding of
HSV-2, despite the absence of clinical lesions [19]. In
Durban, the MIRA study was undertaken from a peri-
urban clinic in Umkomaas and a less urbanised clinic in
Botha’s Hill. The women that visited the clinics were at
higher risk for HIV and STIs since they were residing in
areas termed “hotspots” with excessively high HIV preva-
lence rates ranging from 39-56%. Diagnosis of HSV-2 was
also more common in the hotspots [20].
In this study, we used a cut-off value of 1.1 which has
been previously shown to have reduced sensitivity and
specificity in detecting HSV-2 antibodies [21]. Despite
this limitation, this study was able to identify factors that
Table 1 Socio-demographic, behavioural and biological data associated with Herpes Simplex Virus type −2 (HSV-2) in
women that presented for screening
HSV-2 at the screening: 2,218/3,472 (73%) Univariate analysis Multivariate analysis
Total population
n = 3472 (%)
Odds ratio (95% CI) p-value Odds ratio (95% CI) p-value
Age groups
<25 1430 (41%) 1 1
25-34 1275 (37%) 2.37 (2.00,2.81) <0.001 1.82 (1.49,2.22) <0.001
35+ 767 (22%) 3.18 (2.55,3.95) <0.001 3.49 (2.71,4.49) <0.001
Language spoken
English/other 191 (6%) 1
Zulu 3281 (94%) 5.47 (4.01,7.43) <0.001 -
Level of education
At least high school 904 (26%) 1 1
Less than high school 2568 (74%) 1.68 (1.43,1.98) <0.001 1.26 (1.03,1.53) 0.021
Religion
Other 325 (9% 1
Christian 3147 (91%) 1.72 (1.36,2.18) <0.001 -
Age at sexual debut
>16 years 2073 (60%) 1
16 years or younger 1399 (40%) 1.40 (1.19,1.63) <0.001 -
Marital/cohabitation status
Married/cohabitating 528 (15%) 1
Not married/not cohabitating 2944(85%) 1.54 (1.25,1.89) <0.001 -
Number of life time sexual partners
1 854 (25%) 1 1
2 978 (28%) 2.53 (2.10,3.10) <0.001 1.89 (1.52,2.34) <0.001
3 731 (21%) 3.84 (3.10,4.82) <0.001 2.30 (1.78,2.96) <0.001
4 + 906 (26%) 5.43 (4.33,6.82) <0.001 2.48 (1.92,3.20) <0.001
Condom used (ever)
Yes 2438 (71%) 1
No 1034 (29%) 1.03 (0.88,1.22) 0.689 -
Parity
None 512 (15%) 1 1
>1 2960 (85%) 2.31 (1.90,2.80) <0.001 1.95 (1.54,2.48) <0.001
Contraceptive use (any)
Yes 2692 (78%) 1
No 780 (22%) 1.40 (1.26,1.68) 0.001 -
HIV status at the screening
seronegative 2041 (59%) 1 1 <0.001
seropositive 1431 (41%) 7.38 (6.01,9.10) <0.001 6.31 (5.06,7.88)
Trichomonas vaginalis infection
at the screening
Negative 3242 (94%) 1
Positive 216 (6%) 1.04 (0.76,1.43) 0.786 -
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Table 1 Socio-demographic, behavioural and biological data associated with Herpes Simplex Virus type −2 (HSV-2) in
women that presented for screening (Continued)
Chlamydia trachomatis infection
at the screening
Negative 3149 (91%) 1
Positive 309 (9%) 1.00 (0.77,1.30) 0.999 -
Neisseria gonorrhoea infection at
the screening
Negative 3375 (97%) 1
Positive 97 (3%) 2.28 (1.29,4.05) 0.005 -
Genital signs and symptoms1
Genital epithelial disruption 1
No 3403 (98%) 1 -
Yes 69 (2%) 1.48 (0.62,3.52) 0.372
Genital signs
No 2986 (86%) 1 -
Yes 486 (14%) 0.98 (0.69,1.39) 0.895
Genital discharge 1
No 2500 (72%) 1 -
Yes 972 (28%) 0.94 (0.72,1.22) 0.628
Genital ulcer
No 3264 (94%) 1 -
Yes 208 (6%) 3.16 (1.73,5.74) <0.001
Bacterial Vaginosis infection
No 3160 (91%) 1 -
Yes 312 (9%) 1.32 (0.89,1.96) 0.162
*CI: Confidence Interval.
1In vulva, vaginal or cervical.
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infections and the factors identified in this study are
consistent with previous published findings.The high
sero-prevalence of HSV-2 in the studied population is of
great public health importance since this high risk popu-
lation could contribute to the transmission of future in-
fections particularly HIV. This study provides insight
into the factors that contribute to prevalent HSV-2 infec-
tion. The identification of risk factors for HSV-2 infection
could aid in the development and implementation of per-
sonalized prevention messages for this infection.
We acknowledge the following limitations of our study:
the population studied here volunteered to participate in
an HIV/STI prevention clinical trial and therefore could
be assumed to be at being at more risk for HIV/STIs. Sex-
ual behaviour data was collected by self-report and there-
fore introduces the concept of biasness. The HerpeSelect™
ELISA IgG has been shown to have a reduced sensitivity
and specificity in populations of high HIV prevalence
which could have affected interpretation of the results
[21]. And finally, laboratory tests that identified exactly
which pathogens caused the ulcers as well as furthercharacterization of the clinical symptoms that fell in the
category genital signs would also have made useful dis-
cussion points. And finally, due to the cross-sectional
design of this study, temporal relationships could not be
established.
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